

**NOTICE DECLARING INTENTION TO BE QUALIFIED UNDER
NATIONAL INSTRUMENT 44-101
SHORT FORM PROSPECTUS DISTRIBUTIONS (“NI 44-101”)**

February 9, 2022

TO: British Columbia Securities Commission, as Principal Regulator

AND TO: Alberta Securities Commission
Ontario Securities Commission
Manitoba Securities Commission

Defence Therapeutics Inc. (the “**Issuer**”) intends to be qualified to file a short form prospectus under NI 44-101. The Issuer acknowledges that it must satisfy all applicable qualification criteria prior to filing a preliminary short form prospectus. This notice does not evidence the Issuer’s intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect until withdrawn by the Issuer.

DEFENCE THERAPEUTICS INC.

By: /s/ Sebastien Plouffe
Name: SEBASTIEN PLOUFFE
Title: President and CEO